Reducing attrition in drug development: smart loading preclinical safety assessment
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Entry into the crucial preclinical good laboratory practice (GLP) stage of toxicology testing triggers significant R&D investment yet >20% of AstraZeneca's potential new medicines have been stopped for safety reasons in this GLP phase alone. How could we avoid at least some of these costly failures? An analysis of historical toxicities that caused stopping ('stopping toxicities') showed that >50% were attributable to target organ toxicities emerging within 2 weeks of repeat dosing or to acute cardiovascular risks. By frontloading 2-week repeat-dose toxicity studies and a comprehensive assessment of cardiovascular safety, we anticipate a potential 50% reduction in attrition in the GLP phase. This will reduce animal use overall, save significant R&D costs and improve drug pipeline quality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · cited 2×
“Although a lack of clinical efficacy is the major cause of drug attrition, an unacceptable safety profile is also a major cause of development candidate failure [1, 7, 8], not only in the clinic, but at stages from drug candidate nomination through clinical development to postmarketing surveillance.”
BackgroundHow to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 2×
“The overall decline in R&D productivity in pharmaceuticals over the past two decades is well documented [1, 2, 3, 4] In addition to the clear cost to patients in need of new therapies, the financial and reputational impact of late stage failures to the industry has also been significant.”
BackgroundConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
Phase II and Phase III attrition rates 2011–2012
Arrowsmith, J., & Miller, P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4090 · Cited by 697
Cited by
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029
Franken, H., Mathieson, T., Childs, D., Sweetman, G. M. A., Werner, T., Tögel, I., Doce, C., Gade, S., Bantscheff, M., Drewes, G., et al. (2015) · Nature Protocols · doi:10.1038/nprot.2015.101 · Cited by 659
Stimulated Raman scattering microscopy: an emerging tool for drug discovery
Tipping, W. J., Lee, M., Serrels, A., Brunton, V. G., & Hulme, A. N. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00693g · Cited by 266
Toxicology Strategies for Drug Discovery: Present and Future
Blomme, E. A. G., & Will, Y. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00407 · Cited by 194
Monticello, T. M., Jones, T. W., Dambach, D. M., Potter, D. M., Bolt, M. W., Liu, M., Keller, D. A., Hart, T. K., & Kadambi, V. J. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.09.006 · Cited by 186
“This robust NPV is largely based on the low clinical positive prevalence observed in our database and in the literature, which can be attributed to the fact that compounds entering clinical development have typically cleared many safety hurdles via extensive in silico, in vitro, and in vivo lead optimization screening…”
Background
Metadata
- Authors
- Roberts, R. A., Kavanagh, S. L., Mellor, H. R., Pollard, C. E., Robinson, S., & Platz, S. J.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 19
- Issue
- 3
- Pages
- 341-347
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2045895507
- Cited by
- 87
- References
- 5
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.